Glaxo wins U.S. FDA approval for wider Advair use

Wed Apr 30, 2008 11:55pm BST
 
Email | Print | | Single Page
[-] Text [+]

By Susan Heavey

WASHINGTON (Reuters) - U.S. health regulators have said GlaxoSmithKline Plc's (GSK.L)(GSK.N) Advair is safe and effective to more widely treat patients with chronic obstructive pulmonary disease (COPD), the drugmaker said on Wednesday.

Glaxo's approval comes the same day as rival AstraZeneca Plc (AZN.L) (AZN.N) said it also was seeking U.S. Food and Drug Administration approval to sell its drug Symbicort for COPD.

COPD, an often-fatal lung condition with no cure, is a major market with more than 12 million Americans suffering from the disease, and another 12 million who are likely not diagnosed, according to the National Institutes of Health.

The FDA's approval allows Glaxo to promote its product to COPD patients who experience flare-ups of the disease, which includes emphysema and chronic bronchitis.

In a statement, Glaxo said the FDA also approved the use of Advair to include "not only patients with COPD associated with chronic bronchitis, but also emphysema or both conditions."

Advair already is approved to prevent wheezing and to control other COPD symptoms.

Earlier on Wednesday, AstraZeneca said it had submitted an application to the FDA seeking approval to market Symbicort for COPD based on two clinical trials, setting up competition

for the lucrative market.  Continued...

 
Trading specialists work at the Goldman Sachs booth on the floor of the New York Stock Exchange October 30, 2009.   REUTERS/Brendan McDermid
Insider sales not a sell signal

U.S. corporate bosses are likely to sell more of their companies' stock through to the end of the year, but that does not mean share prices have topped.  Full Article 

Photo

Market Update

  • UKUK
  • USUS
  • Europe
  • Asia
  • UK Most Actives

Most Popular Business News on Reuters UK

  • Articles
  • Videos